Katherine Goodrich insider trades: Tarsus Pharmaceuticals (TARS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Katherine reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | TARS | ↓ Sell | 2,954 | $62.08 | $183K | Direct | Jun 17, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TARS insiders
Open-market trades in the last 12 months
About Katherine Goodrich's insider trades
Katherine Goodrich is a director at Tarsus Pharmaceuticals (TARS). Since Jun 15, 2026, Katherine has reported no open-market purchases and 1 sale worth $183K on SEC Form 4. In the last 12 months: 1 sale ($183K).
Their filings also include grants and awards (3 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TARS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.